Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Recent health updates see UnitedHealth shareholders challenging healthcare denial impacts. BRCA2 cancer gene mutation risks ...

Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

Mr. Knowles is opening up about something else near and dear to his heart — his experience as a male breast cancer survivor ...

And I had my tubes and ovaries removed very soon after my diagnosis of BRCA2, no regrets, no second guessing." Now, Brystowski recommends everyone look into genetic testing to find out their risks ...

For the first time in Nepal, genetic testing, also known as "Gene Sequencing," related to breast cancer (BRCA1 and BRCA2) has ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.